Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Top Cited Papers
Open Access
- 1 May 2019
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 156 (6), 1731-1741
- https://doi.org/10.1053/j.gastro.2019.01.261
Abstract
No abstract availableKeywords
Funding Information
- Bayer
This publication has 30 references indexed in Scilit:
- Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaGenome Research, 2013
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2012
- Molecular signatures database (MSigDB) 3.0Bioinformatics, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular CarcinomaCancer Research, 2009
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular CarcinomaCancer Research, 2008
- Identification of Cystatin B as a Potential Serum Marker in Hepatocellular CarcinomaClinical Cancer Research, 2008
- Transcriptome classification of HCC is related to gene alterations and to new therapeutic targetsJournal of Hepatology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinomaJournal of Hepatology, 2003